Page 24 - Oncology Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Using ultrasound and RNA-loaded nanoparticles to deliver potent medicine to brain tumors RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways. Mostly. So far, these promising drugs haven't been very useful in getting through to the well-protected brain to treat tumors or other maladies. Now a multi-institutional team of researchers, led by Costa...

Georgia Institute of Technology RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways. Mostly. So far, these promising drugs haven’t been very useful in getting through to the well-protected brain to treat tumors or other maladies. Now a multi-institutional team of researchers, led by Costas Arvanitis at the Georgia Institute of Technology and ...

 E-Mail IMAGE: Georgia Tech Mechanical Engineering Ph.D. student Yutong Guo (left) and her mentor, assistant professor Costas Arvanitis, have developed a way to use ultrasonics to treat brain disease. view more  Credit: Ashley Ritchey, Georgia Tech RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality. This rapidly expanding class of therapeutics are cost-effective, fairly easy to manufacture, and able to go where no drug has gone before, reaching previously undruggable pathways. Mostly. So far, these promising dr...

Published: Mar 11, 2021 New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline results in Q1 2021 Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021 Company to host conference call today at ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ... BioXcel TherapeuticsMarch 11, 2021 GMT New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline ...